Market Cap 326.27M
Revenue (ttm) 0.00
Net Income (ttm) -69.63M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 143,500
Avg Vol 124,418
Day's Range N/A - N/A
Shares Out 32.63M
Stochastic %K 70%
Beta 1.05
Analysts Strong Sell
Price Target $19.00

Company Profile

Jade Biosciences, Inc. operates as a biotechnology company that develops therapies for inflammation and immunology indications in patients living with autoimmune diseases. The company develops JADE101, a monoclonal antibody to block the A PRoliferation Inducing Ligand protein, which is in phase 1 clinical trial. It also develops JADE201 and JADE-003, which are in preclinical development stage. The company has a collaboration agreement with Paragon Therapeutics, Inc. Jade Biosciences, Inc. was fo...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 312 3013
Address:
Building 23, Suite 105 221 Crescent Street, Waltham, United States
DiegoModgill
DiegoModgill Oct. 25 at 1:42 AM
$JBIO BlackRock increased its position to 6.6% on this one, smart money is positioning for a parabolic run. Nov 7th
0 · Reply
DiegoModgill
DiegoModgill Oct. 21 at 8:22 AM
$JBIO - Rocket fuelling in - 7th Nov
0 · Reply
DiegoModgill
DiegoModgill Oct. 18 at 5:01 AM
$JBIO - This is one is Chosen
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 10:51 PM
Keep a close watch on CMCT! $PTPI $JBIO $XFOR $STSS a
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 7 at 12:25 PM
$JBIO (+21.7% pre) Jade Biosciences unveils JADE201 antibody for autoimmune diseases https://ooc.bz/l/79520
0 · Reply
topstockalerts
topstockalerts Oct. 7 at 12:06 PM
$JBIO keep it on your radar..
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 7 at 11:44 AM
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 7 at 11:17 AM
$JBIO Jade Biosciences prices 13.4M shares at $9.14 in private placement (JBIO)
0 · Reply
DonCorleone77
DonCorleone77 Oct. 7 at 11:17 AM
$JBIO Jade Biosciences prices 13.4M shares at $9.14 in private placement
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 7 at 11:10 AM
$JBIO JBIO Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases $LLY
0 · Reply
Latest News on JBIO
Jade Biosciences Announces $135 Million Private Placement

Oct 7, 2025, 7:00 AM EDT - 20 days ago

Jade Biosciences Announces $135 Million Private Placement


Jade Biosciences to Participate in Upcoming Conferences

Aug 25, 2025, 7:00 AM EDT - 2 months ago

Jade Biosciences to Participate in Upcoming Conferences


Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jul 1, 2025, 7:00 AM EDT - 4 months ago

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer


DiegoModgill
DiegoModgill Oct. 25 at 1:42 AM
$JBIO BlackRock increased its position to 6.6% on this one, smart money is positioning for a parabolic run. Nov 7th
0 · Reply
DiegoModgill
DiegoModgill Oct. 21 at 8:22 AM
$JBIO - Rocket fuelling in - 7th Nov
0 · Reply
DiegoModgill
DiegoModgill Oct. 18 at 5:01 AM
$JBIO - This is one is Chosen
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 9 at 10:51 PM
Keep a close watch on CMCT! $PTPI $JBIO $XFOR $STSS a
0 · Reply
OpenOutcrier
OpenOutcrier Oct. 7 at 12:25 PM
$JBIO (+21.7% pre) Jade Biosciences unveils JADE201 antibody for autoimmune diseases https://ooc.bz/l/79520
0 · Reply
topstockalerts
topstockalerts Oct. 7 at 12:06 PM
$JBIO keep it on your radar..
0 · Reply
AStrokeOfLuck
AStrokeOfLuck Oct. 7 at 11:44 AM
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 7 at 11:17 AM
$JBIO Jade Biosciences prices 13.4M shares at $9.14 in private placement (JBIO)
0 · Reply
DonCorleone77
DonCorleone77 Oct. 7 at 11:17 AM
$JBIO Jade Biosciences prices 13.4M shares at $9.14 in private placement
0 · Reply
Bullish_Trader555
Bullish_Trader555 Oct. 7 at 11:10 AM
$JBIO JBIO Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody in Development for Autoimmune Diseases $LLY
0 · Reply
RedFlipTrader
RedFlipTrader Oct. 5 at 8:32 AM
$JBIO Biotech with clinical catalyst. High volatility expected. Trading near cash value. Speculative positioning.
0 · Reply
_CircuitBreaker
_CircuitBreaker Oct. 3 at 1:01 AM
0 · Reply
TraderJay85
TraderJay85 Oct. 2 at 2:44 PM
$JBIO Big win! went to 10.17. got in early. We had 16 poppers so far today. If you are not hitting at least 3 runners a day, then you aint doin something right. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER
0 · Reply
TraderJay85
TraderJay85 Oct. 1 at 11:59 PM
PRE-MARKET MOVERS (PMM) $NEXM 5.91 Stop $JBIO 9.20 $HUDI 1.40 $SORA 5.00 $POET 6.11 Never hold under support. if it goes below then sell. Jump back in if it comes back to last support like YDES. NO EMAILS NO DISCORDS JUST FREE IDEAS TO EVERYONE. HIT THE FOLLOW AND LETS MAKE MONEY TOGETHER ❤️
1 · Reply
DiegoModgill
DiegoModgill Sep. 23 at 12:16 PM
$JBIO See snapshot from Fintel No.1 favorite from institutional score
0 · Reply
dogDazeSummer
dogDazeSummer Sep. 9 at 2:43 PM
Only 5 new adds for RA in latest Q: $HNGE $JBIO $TNGX $WGS and a “pipeline in pill” company from Germany, forgot the name. Total holdings are 63 many making ATH today. Interesting focus on immune dermatology. Here’s how much cash he dropped into each new starter position: Might want to follow these 5 names. $15M into Hinge $9.9m into Jade $7.3m into Omada $5.4m into GeneDx $3.2k into Inflarx
1 · Reply
GrowthStrategist
GrowthStrategist Aug. 27 at 10:17 AM
$JBIO hovering near recent highs, careful of a pullback.
0 · Reply
JarvisFlow
JarvisFlow Aug. 14 at 2:03 PM
Wedbush has updated their rating for Jade Biosciences ( $JBIO ) to Outperform with a price target of 18.
0 · Reply
Quantumup
Quantumup Jul. 14 at 7:09 PM
Jefferies🏁 $JBIO Buy-$16 $VRTX $OTSKF Jefferies said in its initiation report: "We like $JBIO's long-acting anti-APRIL (JADE101) in IgAN: 1) our PK work suggests '101 can achieve Q8/12W dosing, 2) we think efficacy will be as good as povetacicept w/ pot'l upside on % clinical remission, 3) we expect tolerable safety profile w/o increased serious infections, 4) we see oppty for disease modifying tx w/ longer dosing interval in IgAN. We model $915M risk-adj. PS for '101 (POS 30%). Co also has $255M cash/cash eq. w/ runway to '27."
0 · Reply
stayput
stayput Jul. 1 at 4:56 PM
$JBIO Still looking for $12
0 · Reply
MONSTER_MOVER_STOCKS
MONSTER_MOVER_STOCKS Jul. 1 at 2:19 AM
$JBIO It's coming...
0 · Reply
Nikolinit
Nikolinit Jun. 23 at 12:59 PM
0 · Reply